Amasyalı Saliha Yeter, Gürses Aslı Akyol, Aydın Osman Nuri, Akyol Ali
Department of Physical Medicine and Rehabilitation, Division of Algology, Turkey.
Department of Neurology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey.
Clin Psychopharmacol Neurosci. 2019 Feb 28;17(1):139-142. doi: 10.9758/cpn.2019.17.1.139.
Treatment of burning mouth syndrome (BMS) is challenging because there is no consensus regarding pharmalogical or nonpharmalogical therapies. The use of anticonvulsants is controversial. We present nine patients BMS who respond to pregabalin. They were diagnosed secondary BMS except two. Etiologic regulations were made firstly in patients with secondary BMS but symptoms did not decrease. We preferred pregabalin in all patients and got good results. Furthermore the addition of pregabalin to the treatment of two patients who did not respond adequately to duloxetine provided good results. We are only aware that pregabalin may reduce symptoms as a result of case reports. We believe that the diagnosis of pathologic etiology with appropriate diagnostic tests will result in better outcomes in treatment.
灼口综合征（BMS）的治疗颇具挑战性，因为在药物治疗或非药物治疗方面尚未达成共识。抗惊厥药的使用存在争议。我们报告了9例对普瑞巴林有反应的灼口综合征患者。除2例患者外，其余均诊断为继发性灼口综合征。对于继发性灼口综合征患者，首先进行了病因调整，但症状并未减轻。我们在所有患者中均选用了普瑞巴林，取得了良好效果。此外，对于另外2例对度洛西汀反应欠佳的患者，在治疗中加用普瑞巴林也取得了良好效果。我们仅通过病例报告了解到普瑞巴林可能减轻症状。我们认为，通过适当的诊断测试明确病理病因将使治疗取得更好的效果。
